In this episode FirstWord Pharma PLUS executive editors Simon King and Michael Flanagan speak further about potential treatment options for COVID-19 (ahead of yet more anecdotal evidence in support of Gilead Sciences’ remdesivir) and the politicisation of different approaches in the absence of meaningful data from controlled clinical studies, discuss the role of antibody diagnostics with FirstWord MedTech editor Tina Tan and weigh up new feedback from physicians which suggests the pandemic is significantly disrupting the management of broader healthcare provision.
Thanks for listening and please do forward any feedback and suggestions to simon.king@firstwordgroup.com
Stay safe
The FirstWord team
To read more Spotlight On articles, click here.
